Floatz logo

Nab-Sirolimus

TSC2

Aadi Bioscience, Inc.Phase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

0 Active assets in the TSC2 cohort.

Asset / SponsorPhaseRating
Everolimus
Dana-Farber Cancer Institute
Phase 2B

Same molecule, other indications

Nab-Sirolimus is also rated in:

neoplasmDormant
B
Indicative ·
60 / 100
View asset →
neoplasmDormant
B
Indicative ·
58 / 100
View asset →
cancerDormant
CCC
Indicative ·
55 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →